What changes brings UK MDR 2026?
The draft UK Medical Devices Regulations (MDR) represent an important shift from the UK MDR 2002 framework driven by the Medicines and Healthcare products Regulatory Agency (MHRA). They move Great Britain away from the old 2002 baseline and align it much more closely with contemporary international regulations like the EU MDR 2017/745 and the International Medical Device Regulators Forum (IMDRF). Some definitions have been clarified and/or expanded. For example, intended purpose includes now information provided by marketing material. The definition of medical devices has been expanded as well.
The main differences between the old 2002 regulations and the new framework focus on a few key areas:
1. The International Reliance Pathway in the new UK MDR draft
Under the 2002 rules, there was no structured, formal mechanism to recognize foreign approvals directly outside of historical EU relationships.
The New Rules: The draft regulations introduce a dedicated, stand-alone International Reliance Pathway. Manufacturers with qualifying devices authorized by comparable regulators in the US (FDA), Canada (Health Canada), and Australia (TGA) can use an accelerated route to access the Great Britain market.
Depending on the risk class (Routes 1, 2, or 3), higher-risk devices can secure a Certificate of International Reliance from a UK Approved Body without undergoing a completely separate UKCA marking process. (Note: The EU is currently handled via separate consultations on indefinite CE-mark recognition).
 |  |  |
2. Risk-Proportionate Product Classification
The UK MDR 2002 relied on a simple, broad definitions for general medical devices.
The New Rules: The draft implements a highly granular, risk-based classification system.
General Devices: Classification rules are modernized to explicitly address Software as a Medical Device (SaMD), nanomaterials, and invasive/implantable devices. While SaMD generally remains Class I in Great Britain (offering a slight point of divergence from current EU MDR Class IIa defaults), it features tight integration into active device provisions.
3. Stringent Post-Market Surveillance (PMS) & Vigilance
The 2002 framework was included relatively generic post-market obligations based on MDD 93/42/EEC requirements.
The New Rules: A dedicated Post-Market Surveillance statutory instrument fundamentally changes the game. It makes structured PMS Plans completely mandatory.
It institutes clear, legally binding requirements for Post-Market Surveillance Reports (PMSR) and Periodic Safety Update Reports (PSUR), scaling by device class and aligning with EU MDR 2017/745.
It also mandates significantly shorter, tighter timelines for reporting serious incidents and enforces stricter data-trending to align with EU MDR 2017/745.
4. Traceability, UDIs, and Implant Cards
The 2002 regulations lacked the technical infrastructure for digital, real-time product tracking.
The New Rules: Unique Device Identifiers (UDIs) are now mandatory for all medical devices and IVDs. Manufacturers must assign three components: a Basic UDI-DI (product group), a UDI-DI (model/manufacturer identification), and a UDI-PI (production metadata like lot numbers and expiry dates).
This data must be logged into a publicly accessible database. For patients receiving high-risk treatments, physical Implant Cards are now required to ensure traceability and long-term transparency.
5. Technical Documentation, Equivalence, & PCCPs
Historically, asserting "equivalence" to clear a device under the 2002 rules was frequently achieved via guidance documents and historical clinical evaluation practices.
The New Rules: The draft builds a different statutory framework for claiming equivalence from EU MDR 2017/745.
Technical documentation requirements are expanded significantly to mirror the depth of Annex II of the EU MDR 2017/745. Retention periods are also extended to the lifetime of the device plus 10 years (or 15 years for implantable devices).
For Software: The draft introduces a statutory Predetermined Change Control Plan (PCCP) mechanism.
6. Truth in Advertising and Claims
The old framework provided sparse direct enforcement mechanisms for marketing language.
The New Rules: The amendment introduces explicit statutory prohibitions against misleading or unsubstantiated claims. Promotional content and labelling must align perfectly with the device’s validated statement of intended purpose, protecting users from exaggerated safety or performance narratives.
Summary of the transition: While the MHRA is planning a phased, transitional approach to prevent supply chain disruption, manufacturers transitioning from the 2002 baseline to the new regulations will need to update their technical documentation, establish robust PMS reporting pipelines, implement UDI, and adapt to the updated risk-classification criteria.
Comments